GlassScriptPhysician profile
Kristina P Shurtleff
NPI 1811916216
$4,455.76
in general payments reported to CMS, 2019-2025
37 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $1,101 · 2021: $821 · 2022: $555 · 2023: $525 · 2024: $95.22 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.93 | 2019-2024 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $318.89 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $306.96 | 2019-2025 | Otezla, Repatha, Otezla |
| Allergan, INC. | $280.20 | 2019-2020 | |
| Novo Nordisk INC | $276.23 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $246.51 | 2021-2023 | Verquvo, Belsomra, Januvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.18 | 2019-2024 | Jardiance |
| Esperion Therapeutics, INC. | $173.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $155.38 | 2019-2023 | Farxiga |
| Janssen Biotech, INC. | $147.63 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $146.14 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.08 | 2019-2025 | Xifaxan, Relistor |
| Mannkind Corporation | $129.44 | 2019-2022 | |
| Pfizer INC. | $127.70 | 2019-2021 | |
| Astellas Pharma US INC | $107.59 | 2019-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Shurtleff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.